BB Biotech stock
BION.SWSIXBB Biotech AG, Financial ServicesISIN CH0038389992
69Score 69 out of 100, Neutral
Price and trend
79 / 100
Price history
+32% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 87).
The price is 3.5% below its 52-week high. Largest decline in 20 years: 73% (February 2021 to April 2025).
Chart figures for advanced users
- SMA 50$61.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$58.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)87
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$49.53
- The lowest closing price of the last twelve months.
- Resistance$68.44
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BB Biotech AG belongs to the Financial (Conglomerates) industry (Switzerland) and, with a market value of $3.64B, is number 16 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $92.56M (down 31.2% year on year) and earnings of $696.65M (up 661.7%).
- MEQIRI Score 69 out of 100 (Neutral): rank 452 of 976 in Financial Services, median 68.
Show more
- The P/E is 2.8 (Financial (Conglomerates) median 17.9, own median of recent years 5.4).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on equityReturn on equity 36.6% over the last 12 months.Profitability 98
- High dividend yieldDividend yield 4.1%, Financial (Conglomerates) median 2.62%.Capital allocation 76
Weaknesses
- Revenue shrinkingRevenue down 35.7% a year since 2020.Growth 9
Its standout strengths are profitability and momentum, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 31.2% on the prior year. Revenue swung sharply, with 5 of 20 years negative.
Margins
- Operating margin
- Net margin
In fiscal 2025: operating 764%, net 753%. Banks and insurers have no gross margin, and their net margin is not comparable with other industries. The score leaves both out. Last 12 months: net 100%.
Debt & balance sheet
latest quarterFor banks and insurers, deposits and liabilities are the business. Debt to equity and the current ratio say little here, and the score does not rate them.
Earnings
- Next earnings
- 22 Jan 2027in 71 days
- Last reported
- 23 Oct 2026EPS reported $3.82
Analyst estimates
- Earnings per share
- $3.110.0%
- Revenue
- $1.54B0.0%
- Earnings per share
- $4.62+89.8%
- Revenue
- $1.54B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at BB Biotech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
976 rated companies in Financial Services
- This company
- 69
- Sector median
- 68
Categories against the sector medianMedian of 976 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Financial (Conglomerates)
The next larger and next smaller companies by market value
- StorebrandSTB.OL $9.01B72
- Authum Investment & InfrastructureAIIL.NS $5.38B70
- Guangzhou Yuexiu Financial Holdings Group000987.SZ $5.14B52
- Compagnie de l'OdetODET.PA $4.69B42
- MandatumMANTA.HE $3.27B54
- Financière MonceyFMONC.PA $2.16B41
- KinnevikKINV-B.ST $2.01B32
- Storskogen GroupSTOR-B.ST $1.99B61
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.